Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival Celebration Sale - 2019
Google
Web www.equitybulls.com
Stock Report

| More

Lupin and Boehringer Ingelheim announce Partnership to Develop and Commercialize Novel Oncology Drug to treat KRAS-driven Cancers

Posted On: 2019-09-04 14:10:09

Boehringer Ingelheim and Lupin Limited (Lupin) have announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer Ingelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Commenting on the partnership, Nilesh Gupta, Managing Director, Lupin Limited said, "With the success of our second new drug discovery program in oncology, we have made a significant mark in bringing novel treatments to patients. Lupin's MEK Inhibitor program successfully cleared early clinical stages, demonstrating our capabilities in delivering world class innovation. We are proud of the achievements of our team and the capabilities we have built which enable us to further our new drug discovery program. We are delighted to partner with Boehringer Ingelheim in developing treatments that w ill truly benefit patients in need".

Dr. Raj Kamboj, President of Lupin's Novel Drug Discovery and Development (NDDD) stated, "The success of our second NDDD program in Oncology has added to our confidence in bringing highly differentiated and best-in-class innovation from India for patients globally. Carrying forward our founder, Dr. Desh Bandhu Gupta's dream in shaping true innovation, we have delivered a novel treatment from conceptualization to clinical stage development with promising results that can be a potential combination treatment for precision oncology."

"The licensing of Lupin's novel MEK inhibitor enables us to pair with our innovative KRAS inhibitors to develop new combination treatment concepts providing more effect ive and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available," said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim. "We believe this collaboration will significantly strengthen our KRAS program. We have developed comprehensive approaches to successfully tackle the oncogenic KRAS - RAF - MEK - ERK pathway from the ground up and this partnership is another key building block in our long-term strategy to bring novel treatments to patients in our quest to defeat intractable cancer types."

The collaboration has a strategic goal to focus on patients with gastrointestinal or lung cancers defined by KRAS mutations, sub-populations that currently need more effective therapeutic options. KRAS mutations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 perce nt in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. Preclinical data has shown that the combination of Boehringer Ingelheim's novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check.

Lupin's MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients. Lupin's Novel Drug Discovery and Development team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the therapeutic areas of oncology, immunology and metabolic disorders. Lupin's NDDD activities were started with the vision to use cutting-edge research in bringing novel molecules that address unmet medical needs in multiple therapeutic areas to market globally.

Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total deal value of more than $700 million. Additionally, Lu pin will be entitled to receive double-digit roya lties on the sales of the product.

Shares of LUPIN LTD. was last trading in BSE at Rs.733.5 as compared to the previous close of Rs. 740.25. The total number of shares traded during the day was 27442 in over 878 trades.

The stock hit an intraday high of Rs. 745.85 and intraday low of 730.8. The net turnover during the day was Rs. 20268571.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Indiabulls Housing Finance Ltd issues offer to debenture holders of NCDs maturing in November, December for pre-mature redemption

LTI Constant Currency Revenue growth up 11.9% YoY

Patel Integrated Logistics Ltd board approves rights issue

Cipla acquires novel anti-infective Elores to further antimicrobial stewardship in critical care in India

I S T Ltd Board approves Sub-division of equity shares

CRISIL reaffirms long-term rating of Indiabulls Housing Finance Ltd

DIL Limited is now Fermenta Biotech Ltd

Jay Bharat Maruti Ltd Q2 consolidated PAT drops to Rs. 3.76 crore

Larsen & Toubro Infotech Ltd board declares first interim dividend of Rs. 12.50 for FY2019-20

Hero MotoCorp announces 5th edition of The Hero Campus Challenge

ZEE Entertainment posts strong performance in a challenging environment

Shemaroo Entertainment Ltd to raise Rs. 250 crores

Larsen & Toubro Infotech Ltd to acquire PowerupCloud

CARE A+ rating assigned to JMC Projects' NCD issue

Brickwork Ratings assigns credit ratings to Vikas EcoTech Ltd

Shemaroo Entertainment Ltd Q2 FY 2019-20 consolidated net profit at Rs. 19.49 crores

ZEE Entertainment Enterprises Ltd posts consolidate PAT of Rs. 413.23 crores in Q2

Larsen & Toubro Infotech Ltd Q2 consolidated PAT at Rs. 360.1 crore

Cyient Ltd announces Q2 FY2019-20 results

TVS Motor Company's EBITDA increased from 8.6% in Q2 of FY 2018-19 to 8.8% in Q2 of FY 2019-20

Mastek Ltd Q2FY20 Total Income at Rs 252.7 crore

Ind-Ra affirms India Glycols Ltd's long-term rating

AksharChem India Ltd announces shutdown of Vinyl Sulphone plant for repairs and maintenance

FDC Ltd to acquire 'ENTEROPLUS' from GlaxoSmithKline Pharmaceuticals Ltd

Only 17 Percent of Banks have Deployed Digital at Scale - Finds Infosys Finacle and Efma 'Innovation in Retail Banking' Report

Alicon Castalloy signs multi-year Contracts aggregating 810 crore with leading Global OEMs and Tier 1 Suppliers

PTron Launches advanced version of Dual Driver Earphones - Boom 3

SEAMEC PRINCESS on hire with Posh Subsea Pte Limited

Cyient Ltd board recommends interim dividend of Rs. 6 for 2019-20

South Indian Bank Ltd Q2 PAT higher at Rs. 84.48 crore

3I Infotech Ltd reports consolidated PAT of Rs. 13.35 crore in Q2

Automotive Stampings & Assemblies Ltd posts loss of Rs. 1.18 crore in Q2

Mastek Ltd Board approves Dividend of Rs. 3 for 2019-20

Pennar Industries bags orders worth INR 304 Crore

TVS Motor Company Ltd reports consolidated net profit of Rs. 253.57 crores in Q2

Chennai Petroleum Corporation Ltd Q2 loss at Rs. 213.64 crore

FORCE Motors Ltd reports Q2 FY 2019-20 net profit of Rs. 4.21 crore

MASTEK Ltd posts consolidated Q2 net profit of Rs. 24.64 crores

AMAL Ltd reports net profit of Rs. 2.35 crore in Q2 FY 2019-20

PVR Ltd Q2 consolidated PAT soars to Rs. 47.67 crores

Chartered Logistics receives award from JSW Cement

Home Credit India and Karur Vysya Bank tie up for an unique Joint Lending partnership

HCL Technologies selected as one of Volvo Cars' main suppliers for digital transformation and IT Services

NIIT recognised as 'Vocational & Skill Development Training Institute' at Franchise Awards 2019

ICRA reaffirms ratings of International Combustion (India) Limited

Ab Sabka Combo Chalega - McDonald's India (West and South) launches two quirky TVCs to promote their festive offer

Prakash Industries Limited commences commercial production from its 5th Sponge Iron Rotary Kiln

Vodafone Idea extends strategic partnership with TCS to enhance Customer Experience

RAH Infotech forges strategic partnership with Tata Communications for Cloud Offerings

Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019